Except CCL2, these MKX target genes show conspicuous activity in myelopoiesis at the IRX1-positive MEP stage, highlighting this developmental progenitor as a candidate cell of origin in AML cases aberrantly expressing IRX1-related MKX. This evidence concerns the gene MKX and acute myeloid leukemia.